📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-21 16:48
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
28 announcements match the current filters (relevance ≥ 5).
Q1 FY27: ₹40.3 Cr Revenue, Highest in 16 Quarters; PAT Turns Positive at ₹3.1 Cr
Nureca reported a strong operational turnaround in Q1 FY27, achieving its highest quarterly revenue in four years at ₹40.3 Cr, an 18% YoY increase. The company returned to profitability with a PAT of ₹3.1 Cr, recovering from a ₹6.09 Cr loss in the preceding quarter (Mar 2026). A key highlight is the company's liquidity, with ₹110 Cr in net cash and investments, which represents approximately 37% of its current market capitalization of ₹299 Cr. The shift toward in-house manufacturing is progressing, now contributing 27% of total revenue.
Confidence: HIGH
What changedThe company has successfully pivoted from a loss-making quarter to its highest sales and profitability in 16 quarters, backed by a debt-free balance sheet.
Why it mattersThe turnaround validates Nureca's strategy of reducing import dependence through domestic manufacturing and leveraging its 'Dr Trust' brand across omnichannel platforms.
Q1 FY27 Revenue: ₹40.3 CrQ1 FY27 PAT: ₹3.1 CrNet Cash & Investments: ₹110 CrCash to Market Cap Ratio: ~36.8%In-house Manufacturing Share: 27%Gross Margin: 38.8%
📅 Short termThe stock may see positive momentum as the market reacts to the sharp recovery in profitability and the strong cash position.
📈 Long termThe transition to a manufacturing-led model and the expansion of the Punjab facility could structurally improve margins and reduce supply chain risks over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High reliance on e-commerce marketplaces (>93% sales)
- Platform concentration risk
- High P/E ratio of 143.4 relative to historical earnings
Key Highlights
Revenue of ₹40.3 Cr represents a 14% QoQ and 18% YoY growth, the highest since Q4 FY22.
PAT turned positive at ₹3.1 Cr compared to a loss of ₹6.09 Cr in Q4 FY26.
Net cash and investments stand at ₹110 Cr, providing a significant valuation floor relative to the ₹299 Cr market cap.
In-house manufacturing contribution reached 27% of revenue in Q1 FY27, up from 26% in FY26.
Dr Trust 360 app user base expanded to 2.4 million users, strengthening the digital health ecosystem.
👀 What to Watch
Investors should monitor the execution timeline of the new medical device facility at Sundran, Punjab, and track if the operating margin (currently 8.7%) continues to expand as manufacturing-led growth replaces the pure trading model.
CEO Aryan Goyal Resigns Following Family Settlement Agreement
Mr. Aryan Goyal has resigned as Whole-time Director and CEO of Nureca Limited, effective July 01, 2026. This departure is a result of a Family Settlement Agreement dated June 17, 2026, which includes the transfer of his entire shareholding to Mr. Saurabh Goyal. The transition comes at a time when the company reported a net loss of ₹6.09 Cr in the March 2026 quarter and maintains a thin TTM operating margin of 0.1%. Investors should note that the exit is structural rather than performance-based, though leadership stability is critical given the recent quarterly volatility.
Confidence: HIGH
What changedThe CEO and Whole-time Director is stepping down and exiting his equity stake in the company due to a private family settlement.
Why it mattersLeadership changes in small-cap companies (TTM Revenue ₹147 Cr) can lead to shifts in strategic execution, especially as the company navigates low profitability (ROCE 2.0%) and high reliance on e-commerce platforms.
Effective Date of Cessation: July 01, 2026Family Settlement Date: June 17, 2026TTM Revenue: ₹147 CrMar 2026 Net Profit/Loss: ₹-6.09 CrTTM Operating Margin: 0.1%
📅 Short termThe stock may see neutral to cautious sentiment as the market digests the exit of a key promoter-director and waits for clarity on the new leadership structure.
📈 Long termThe consolidation of shareholding under one family member may streamline decision-making, but the company must demonstrate a path back to consistent profitability after the Mar 2026 loss.
⚠ Risk flags
- Management transition risk
- High reliance on e-commerce marketplaces (>93% sales)
- Recent quarterly net loss
Key Highlights
Cessation of Mr. Aryan Goyal as CEO and Whole-time Director effective July 01, 2026.
Resignation triggered by a Family Settlement Agreement dated June 17, 2026.
Entire shareholding of the outgoing CEO is being concurrently transferred to Mr. Saurabh Goyal.
Company reported TTM Revenue of ₹147 Cr with a marginal TTM PAT of ₹2 Cr.
Latest quarterly results (Mar 2026) showed a net loss of ₹6.09 Cr on revenue of ₹35.41 Cr.
👀 What to Watch
Monitor the official appointment of a successor CEO and any subsequent changes in the 'Digital First' strategy or product portfolio management under the consolidated leadership of Saurabh Goyal.
Nureca's Dr Trust 360 Crosses 2.4 Million Users; Launches AI Health Analytics Suite
Nureca Limited has reached a significant milestone with its Dr Trust 360 platform surpassing 2.4 million registered users. The company is expanding its digital ecosystem by launching 'Dr Trust Intelligence,' an AI-powered analytics suite that provides personalized health insights and trend detection. This new feature is positioned as a premium subscription service, indicating a strategic shift towards recurring digital revenue. Additionally, the company emphasized its data security by hosting health data on Indian servers to comply with local regulations.
Key Highlights
Dr Trust 360 platform reached a milestone of 2.4 million registered users.
Launched 'Dr Trust Intelligence,' an AI-driven suite for body-composition analysis and diet plans.
New 8-electrode smart scales claim up to 98% DEXA-level accuracy for key health metrics.
Monetization strategy introduced through premium subscriptions on Android and iOS apps.
Nureca's total customer base stands at over 1.86 crore (18.6 million) across its brands.
👀 What to Watch
Investors should monitor the adoption rate of the new premium AI subscription service, as it represents a high-margin revenue stream compared to traditional hardware sales.
Nureca Promoters Sign Family Settlement; Saurabh Goyal to Consolidate 68.09% Stake
Nureca Limited has been informed of a Family Settlement Agreement (FSA) among its promoter group members to re-align ownership and management. Under the agreement, Mr. Aryan Goyal and Ms. Payal Goyal will transfer their entire 33.74% stake to the sole promoter, Mr. Saurabh Goyal. This will increase Saurabh Goyal's individual holding from 34.35% to 68.09%, consolidating control. Additionally, Mr. Aryan Goyal will resign from his roles as CEO and Director of the company.
Key Highlights
Saurabh Goyal to increase stake from 34.35% to 68.09% via inter-se transfer of 32,19,113 shares
Mr. Aryan Goyal and Ms. Payal Goyal to exit their combined 33.74% shareholding completely
Mr. Aryan Goyal to step down from the position of CEO and resign as a Director
The transaction is exempt from SEBI SAST open offer obligations under Regulation 10(1)(a)
👀 What to Watch
Investors should monitor the impact of the CEO's exit on company operations and the subsequent transition in leadership. While the consolidation of control under the Chairman & MD may streamline decision-making, the loss of a key executive warrants a cautious watch.
Nureca Promoter Saurabh Goyal Acquires 60,842 Shares Worth Rs 1.44 Crore
Mr. Saurabh Goyal, a promoter and director of Nureca Limited, acquired 60,842 equity shares through an off-market transaction on June 9, 2026. The total value of this acquisition is approximately Rs 1.44 crore. This purchase has increased his individual shareholding from 33.72% to 34.35%. Promoter buying is generally viewed as a positive signal indicating confidence in the company's future prospects.
Key Highlights
Promoter Saurabh Goyal acquired 60,842 shares via an off-market transaction.
The total transaction value is approximately Rs 1.44 crore (Rs 1,43,70,880).
The promoter's stake increased by 0.63%, moving from 33.72% to 34.35%.
The transaction was reported under SEBI Prohibition of Insider Trading Regulations.
👀 What to Watch
Investors should take this as a sign of promoter confidence in the company's valuation. While positive, it is advisable to monitor upcoming quarterly results to ensure fundamental performance aligns with this insider sentiment.
Promoter Saurabh Goyal acquires 60,842 shares of Nureca Ltd via off-market transaction
Mr. Saurabh Goyal, a Promoter and Director of Nureca Limited, has acquired 60,842 equity shares of the company through an off-market transaction on June 09, 2026. The acquisition, valued at approximately Rs. 1.44 crore, has increased his individual shareholding from 33.72% to 34.35%. This disclosure was made under SEBI (Prohibition of Insider Trading) Regulations as a matter of abundant precaution.
Key Highlights
Promoter Saurabh Goyal purchased 60,842 equity shares worth Rs. 1,43,70,880.
The transaction was executed off-market on June 09, 2026.
Promoter's total shareholding increased from 32,17,214 shares (33.72%) to 32,78,056 shares (34.35%).
The acquisition represents a 0.63% increase in the promoter's individual stake in the company.
👀 What to Watch
Promoter buying is typically a sign of confidence in the company's future performance. Investors should view this as a positive signal but continue to monitor overall business fundamentals and market conditions.
Nureca Limited Revises Incremental Capex Upward to ₹128 Crores for Expansion
Nureca Limited has issued a corrigendum to its previous board meeting outcome, increasing the planned incremental capital expenditure (capex) from ₹100 crores to ₹128 crores. This investment is specifically earmarked for plant and machinery to manufacture medical devices, healthcare consumables, and hygiene products at its Punjab facility. Furthermore, the board has confirmed the approval for purchasing additional land adjacent to its current site in Dera Bassi for future expansion. This revision reflects a 28% increase in the initially reported capex commitment, signaling a more robust growth plan.
Key Highlights
Incremental capex revised from ₹100 crores to ₹128 crores to rectify a typographical error.
Investment focused on manufacturing medical devices and healthcare consumables in Dera Bassi, Punjab.
Board approved the purchase of additional land adjoining the existing industrial site for future growth.
The expansion targets high-growth segments including hygiene products and medical consumables.
👀 What to Watch
Investors should monitor the company's debt-to-equity ratio and funding sources for this ₹128 crore investment. The increased capex commitment is a positive signal for long-term capacity building and revenue potential.
Nureca Ltd Approves ₹100 Cr Capex and Appoints Chander Kant as New CFO
Nureca Limited has announced a significant expansion plan involving an incremental capex of up to ₹100 crores for manufacturing medical devices and healthcare consumables in Punjab. The company is undergoing a leadership transition with Mr. Chander Kant appointed as the new CFO, effective June 27, 2026, following the resignation of Mr. Naresh Gupta. Additionally, the board has secured leadership continuity by re-appointing the CEO and Managing Director for three-year terms and approving the acquisition of additional land for future growth.
Key Highlights
Approved incremental capex of up to ₹100 crores for plant and machinery at the Sundran, Punjab facility.
Appointed Mr. Chander Kant as CFO and Key Managerial Personnel effective June 27, 2026.
Re-appointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for further 3-year terms starting in 2027 and 2026 respectively.
Approved the purchase of additional land adjoining existing industrial land for future expansion needs.
Accepted the resignation of outgoing CFO Mr. Naresh Gupta, effective June 26, 2026.
👀 What to Watch
Investors should view the ₹100 crore capex as a strong growth indicator for the company's manufacturing capabilities, while monitoring the smooth transition of the new CFO and the execution of the expansion project.
Nureca Approves ₹100 Cr Capex for Expansion and Announces Major Management Changes
Nureca Limited has approved a significant incremental capital expenditure of up to ₹100 crores to expand its manufacturing capacity for medical devices and healthcare consumables in Punjab. The company is undergoing a leadership transition with Mr. Chander Kant appointed as the new CFO effective June 27, 2026, following the resignation of Mr. Naresh Gupta. Furthermore, the board has secured management continuity by re-appointing the CEO and MD for three-year terms and adding Ms. Smita Goyal as a Whole Time Director. The 10th Annual General Meeting is scheduled for July 28, 2026.
Key Highlights
Approved incremental capex of up to ₹100 crores for manufacturing medical devices and hygiene products at the Sundran, Punjab facility.
Appointed Mr. Chander Kant as CFO and KMP effective June 27, 2026, succeeding the outgoing CFO Mr. Naresh Gupta.
Re-appointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for three-year terms starting May 2027 and September 2026 respectively.
Authorized the purchase of additional land adjoining existing industrial plots in Dera Bassi for future expansion needs.
Fixed the 10th AGM date for July 28, 2026, with the share transfer books closing from July 22 to July 28, 2026.
👀 What to Watch
Investors should view the ₹100 crore capex commitment as a strong signal of growth and a move towards backward integration in manufacturing. Monitor the transition of the new CFO and the progress of the facility expansion for impact on future margins.
Nureca Approves ₹100 Cr Capex, Appoints New CFO, and Re-appoints Key Management
Nureca Limited has announced a significant leadership transition and expansion plan following its board meeting on May 29, 2026. The company appointed Chander Kant as the new CFO effective June 27, 2026, and re-appointed Saurabh Goyal as Managing Director for a three-year term. Crucially, the board approved an incremental capital expenditure of up to ₹100 crores for manufacturing medical devices and hygiene products at its Punjab facility. Additionally, the company is acquiring adjoining land for future expansion, signaling a strong growth outlook despite the resignation of the previous CFO.
Key Highlights
Approved incremental Capex of up to ₹100 crores for medical device and hygiene product manufacturing in Punjab
Appointed Chander Kant as CFO effective June 27, 2026, succeeding Naresh Gupta
Re-appointed Saurabh Goyal as Managing Director for a 3-year term starting September 03, 2026
Approved the purchase of additional land adjoining the existing Sundran, Dera Bassi site for future expansion
Re-appointed Aryan Goyal as CEO and Whole Time Director for a 3-year term starting May 2027
👀 What to Watch
Investors should monitor the execution of the ₹100 crore Capex plan as it indicates a strategic shift towards increased in-house manufacturing. The leadership transition appears stable, but the detailed FY26 financial results should be reviewed to assess the company's current valuation relative to these growth plans.
Nureca Approves ₹100 Cr Capex for Expansion and Re-appoints Top Management
Nureca Limited's board has approved a significant incremental capital expenditure of up to ₹100 crores to expand manufacturing capabilities for medical devices and hygiene products at its Punjab facility. The company also announced a leadership transition, appointing Mr. Chander Kant as the new CFO effective June 27, 2026, following the resignation of Mr. Naresh Gupta. Furthermore, the board approved the re-appointment of CEO Mr. Aryan Goyal and MD Mr. Saurabh Goyal for three-year terms, ensuring management continuity. These strategic moves, alongside the purchase of additional land for future growth, signal a strong focus on scaling domestic production and long-term expansion.
Key Highlights
Approved incremental Capex of up to ₹100 crores for manufacturing medical devices and consumables in Punjab.
Appointed Mr. Chander Kant as CFO effective June 27, 2026, succeeding Mr. Naresh Gupta.
Re-appointed CEO Aryan Goyal and MD Saurabh Goyal for 3-year terms starting in 2027 and 2026 respectively.
Board approved the purchase of additional land adjoining the existing Punjab facility for future expansion.
10th Annual General Meeting (AGM) scheduled for July 28, 2026, with book closure starting July 22, 2026.
👀 What to Watch
Investors should monitor the execution of the ₹100 crore capex and its impact on margins as the company increases in-house manufacturing. The management continuity is a positive sign, though the CFO transition should be observed for smooth financial reporting.
Nureca Limited Approves ₹100 Cr Capex and Announces Major Management Reshuffle
Nureca Limited has announced a significant incremental capex of up to ₹100 crore to expand its manufacturing capabilities for medical devices and hygiene products in Punjab. The company is also undergoing a leadership transition, appointing Mr. Chander Kant as the new CFO effective June 27, 2026, following the resignation of the incumbent. Furthermore, the board has approved the re-appointment of the CEO and MD for three-year terms and the appointment of a new Whole Time Director, ensuring leadership continuity for the next expansion phase.
Key Highlights
Approved incremental capex of up to ₹100 crore for manufacturing medical devices and healthcare consumables in Punjab.
Appointed Mr. Chander Kant as CFO and Key Managerial Personnel effective June 27, 2026.
Re-appointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for 3-year terms starting in 2027 and 2026 respectively.
Authorized the purchase of additional land adjoining existing facilities in Dera Bassi for future expansion.
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
👀 What to Watch
Investors should view the ₹100 crore capex as a strong growth signal and monitor the execution timeline of the new manufacturing capacity. The management continuity within the promoter family provides stability, though the transition to a new CFO should be watched for any changes in financial strategy.
Nureca Ltd Approves ₹100 Cr Capex for Expansion and Appoints New CFO
Nureca Limited has announced a major expansion plan with an approved incremental capex of up to ₹100 crores for manufacturing medical devices and healthcare consumables at its Punjab facility. The company is also seeing a management shift as Mr. Chander Kant is appointed as the new CFO effective June 27, 2026, replacing Mr. Naresh Gupta. Furthermore, the board has approved the re-appointment of the current CEO and MD for three-year terms, ensuring leadership continuity. The 10th Annual General Meeting is set for July 28, 2026, with July 21, 2026, as the record date for voting eligibility.
Key Highlights
Approved incremental capex of up to ₹100 crores for medical device manufacturing in Punjab.
Mr. Chander Kant appointed as CFO effective June 27, 2026, following Naresh Gupta's resignation.
Re-appointment of CEO Aryan Goyal and MD Saurabh Goyal for 3-year terms approved.
Record date for 10th AGM e-voting set for July 21, 2026; AGM to be held on July 28, 2026.
Board approved purchasing additional land adjoining the existing site for future expansion.
👀 What to Watch
Investors should monitor the execution of the ₹100 crore capex and its impact on future margins. The leadership continuity and expansion plans suggest a strong growth focus for the upcoming years.
Nureca Limited Approves ₹100 Cr Capex for Expansion and Appoints New CFO
Nureca Limited has announced a major strategic expansion, approving an incremental capital expenditure of up to ₹100 crores for manufacturing medical devices and hygiene products at its Punjab facility. The company is also undergoing a leadership transition with Mr. Chander Kant appointed as the new CFO effective June 27, 2026, following the resignation of Mr. Naresh Gupta. Furthermore, the board has approved the re-appointment of the CEO and MD for three-year terms and the acquisition of additional land for future growth. These developments, alongside the approval of FY26 audited results, signal a strong focus on scaling internal manufacturing capabilities.
Key Highlights
Approved incremental capex of up to ₹100 crores for manufacturing medical devices and healthcare consumables in Punjab.
Mr. Chander Kant appointed as CFO effective June 27, 2026, succeeding outgoing CFO Mr. Naresh Gupta.
Re-appointed CEO Aryan Goyal and MD Saurabh Goyal for three-year terms starting in 2027 and 2026 respectively.
Authorized the purchase of additional land in Dera Bassi, Punjab, to facilitate future industrial expansion.
The 10th Annual General Meeting (AGM) is scheduled for July 28, 2026, with book closure starting July 22, 2026.
👀 What to Watch
Investors should view the ₹100 crore capex as a significant growth catalyst that could improve margins through in-house manufacturing. Monitor the CFO transition and the upcoming detailed FY26 financial results to evaluate the company's capital allocation efficiency.
Nureca Ltd Approves ₹100 Cr Capex, Appoints New CFO, and Re-appoints Key Leadership
Nureca Limited has announced a significant leadership transition with the resignation of CFO Naresh Gupta and the promotion of Chander Kant to the role effective June 27, 2026. The board also approved a major expansion plan involving an incremental capex of up to ₹100 crores for manufacturing medical devices and hygiene products in Punjab. Key promoters Aryan Goyal and Saurabh Goyal have been re-appointed for three-year terms, ensuring leadership continuity. Additionally, the company reported audited financial results for FY26 with an unmodified auditor's opinion.
Key Highlights
Approved incremental capex of up to ₹100 crores for medical device manufacturing in Sundran, Punjab.
Appointed Chander Kant as CFO effective June 27, 2026, following the resignation of Naresh Gupta.
Re-appointed Aryan Goyal (CEO) and Saurabh Goyal (MD) for 3-year terms starting 2027 and 2026 respectively.
Approved the purchase of additional land adjoining existing facilities for future expansion.
Audited financial results for FY26 approved with an unmodified statutory auditor's report.
👀 What to Watch
Investors should monitor the execution of the ₹100 crore capex plan and the transition of the new CFO to ensure operational stability. The re-appointment of promoters provides long-term leadership clarity for the company.
Nureca FY26 Turnaround: Operating Profit at ₹8.5 Cr; Q4 PAT Impacted by Investment Losses
Nureca Limited achieved a significant operational turnaround in FY26, posting an operating profit of ₹8.5 Cr compared to a loss of ₹7.5 Cr in FY25. Annual revenue grew 34% YoY to ₹146.96 Cr, driven by its digital-first strategy where 90% of sales are online. However, Q4 FY26 saw a net loss of ₹6.1 Cr primarily due to non-cash fair value changes in investments. The company remains debt-free and is aggressively expanding its offline distribution network and in-house manufacturing capabilities.
Key Highlights
FY26 Revenue increased by 34% YoY to ₹146.96 Cr from ₹109.7 Cr in FY25.
Operational turnaround achieved with FY26 operating profit of ₹8.5 Cr vs a loss of ₹7.5 Cr in the previous year.
Q4 FY26 PAT was a loss of ₹6.1 Cr due to 'Fair value changes and net loss on investment' under Ind AS compliance.
Company remains debt-free and completed a share buyback worth ₹15.7 Cr during the period.
Offline footprint expanded to 285+ distributors across 29 states and Union Territories.
👀 What to Watch
Investors should focus on the core operational turnaround and rising revenue, while discounting the Q4 PAT loss which was driven by non-operating investment volatility. Monitor if the company can maintain operating margins above 5% while scaling its offline distribution and in-house manufacturing.
Nureca Ltd Approves ₹100 Cr Capex for Expansion and Announces Major Management Changes
Nureca Limited has approved a significant incremental capex of up to ₹100 crores to expand manufacturing capacity for medical devices and healthcare consumables at its Punjab facility. The company also announced a transition in the CFO role, with Mr. Chander Kant succeeding Mr. Naresh Gupta effective June 27, 2026. Additionally, the Board approved the re-appointment of the CEO and MD for three-year terms and the appointment of Ms. Smita Goyal as a Whole Time Director. The company reported audited financial results for FY26 with an unmodified auditor's opinion.
Key Highlights
Approved incremental capex of up to ₹100 crores for medical device manufacturing in Derabassi, Punjab.
Mr. Chander Kant appointed as CFO effective June 27, 2026, following the resignation of Mr. Naresh Gupta.
Re-appointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD) for 3-year terms to ensure leadership continuity.
Board approved the purchase of additional land adjoining existing facilities for future expansion needs.
The 10th Annual General Meeting is scheduled for July 28, 2026, with book closure starting July 22, 2026.
👀 What to Watch
Investors should monitor the execution timeline of the ₹100 crore capex plan as it signals a significant scale-up in manufacturing. The leadership continuity and expansion plans are positive indicators for long-term growth.
Nureca Deposits ₹57.13 Lakh with DRI Over Product Classification Dispute
Nureca Limited has informed the exchanges regarding a hearing with the Directorate of Revenue Intelligence (DRI) concerning product classification under the Customs Act, 1962. Following the hearing held on May 13, 2026, the company has made a pre-deposit of INR 57,12,811 with the authorities. The company clarified that this payment is made without prejudice to its legal rights and does not constitute an admission of liability. As of now, no formal order has been issued by the DRI, and the company is awaiting further developments.
Key Highlights
Hearing conducted by DRI on May 13, 2026, regarding product classification under Section 108 of the Customs Act.
Company made a pre-deposit of INR 57,12,811 (approximately ₹57.13 lakh) during ongoing proceedings.
The payment is made without prejudice and does not represent an admission of liability by Nureca.
No formal order has been issued by the DRI as of the announcement date of May 24, 2026.
👀 What to Watch
Investors should monitor for the final order from the DRI, as an adverse ruling on product classification could lead to higher import duties and impact future margins. While the current deposit amount is manageable, the final classification will determine the long-term tax liability for the company's product range.
Nureca Promoters' Stake Rises to 68.09% Following Share Buyback Extinguishment
Nureca Limited's promoter group has seen their collective shareholding increase from 64.97% to 68.09%. This change is a direct result of the company's recent buyback program, which concluded with the extinguishment of 4,58,255 equity shares on January 07, 2026. While the absolute number of shares held by the promoters remained unchanged at 64,97,176, the reduction in the total share capital base led to a 3.12% increase in their voting rights. This transaction is exempt from open offer requirements under SEBI (SAST) Regulation 10(4)(c).
Key Highlights
Promoter group stake increased by 3.12% to reach a total of 68.09% of the company.
Total equity share capital reduced from 1,00,00,175 to 95,41,920 shares post-extinguishment.
A total of 4,58,255 shares, representing approximately 4.58% of the pre-buyback capital, were extinguished.
Individual promoter Saurabh Goyal's stake increased from 32.17% to 33.72% without purchasing new shares.
The disclosure was filed under Regulation 10(6) of SEBI (SAST) Regulations, 2011.
👀 What to Watch
The increase in promoter stake via buyback is a positive signal of management's confidence in the company's valuation. Investors should look for improvements in Earnings Per Share (EPS) as a result of the reduced share count in future financial reports.
Nureca Q3 FY26: PAT Surges 233% YoY to ₹3.7 Cr; Revenue Up 27% to ₹54 Cr
Nureca Limited reported a strong financial performance for Q3 FY26, with revenue growing 27% YoY to INR 540 Mn. The company achieved a significant turnaround in profitability, posting a PAT of INR 37 Mn compared to a loss of INR 28 Mn in the same quarter last year. EBITDA saw a massive 314% YoY jump to INR 54 Mn, reflecting improved operational efficiency and a 10% margin. The company remains debt-free and continues to derive over 90% of its revenue from digital channels, supported by a cumulative customer base of 17.5 million.
Key Highlights
Q3 FY26 Revenue grew 27% YoY to INR 540 Mn; 9M FY26 revenue reached INR 1,536 Mn.
PAT turned positive at INR 37 Mn in Q3 FY26, a 233% increase from a loss of INR 28 Mn in Q3 FY25.
EBITDA for Q3 FY26 stood at INR 54 Mn (10% margin) compared to INR 25.4 Mn in the previous year.
The company is debt-free with a healthy current ratio of 9.6 and a cumulative customer base of 17.5 million.
Digital-first strategy remains dominant with over 90% of revenue generated through online sales.
👀 What to Watch
Investors should take note of the significant turnaround in profitability and the company's successful transition to a higher-margin, asset-light model. Monitor the progress of the delayed Punjab manufacturing site and the monetization of the 'Dr Trust 360' app as future growth drivers.
